Stock listing

Frankfurt:EU6 PDS Biotechnology Corporation Aktie

German listing (Frankfurt) of PDS Biotechnology Corporation · home listing NASDAQ:PDSB

Follow PDS Biotechnology Corporation into a list and get an email when it puts out news.

Home listing price · NASDAQ:PDSB

$0.777 USD -0.007 (-0.9%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PDSB

Past year +2.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.770 – $0.845 USDNov 20, 2026
Volume
2.89M sharesNov 20, 2026
Market cap
$95.39M USDAt the close on Nov 20, 2026 · price × 122.7M shares outstanding
52-week range
$0.195 – $1.790 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$17.04M USDMedian day 4.88M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
PDS Biotechnology Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PDSB · Home$0.777 USD-0.007 (-0.9%)2,893,951$0.800$0.845$0.770$0.784Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PDSB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.777-0.007-0.9%$0.800$0.845$0.7702,893,951
$0.784-0.110-12.3%$0.907$0.921$0.7624,262,607
$0.894-0.030-3.3%$0.925$0.980$0.8883,507,932
$0.924+0.051+5.9%$0.809$0.969$0.8095,249,300
$0.873-0.107-11.0%$0.990$0.990$0.7505,925,095
$0.980-0.040-3.9%$0.970$1.020$0.9202,882,877
$1.020-0.010-1.0%$1.040$1.050$0.9802,824,770
$1.030-0.050-4.6%$1.015$1.050$0.9444,284,014
$1.080-0.150-12.2%$1.160$1.160$1.0204,073,436
$1.230+0.060+5.1%$1.190$1.270$1.1742,923,610
$1.170-0.130-10.0%$1.280$1.285$1.1303,565,467
$1.300-0.110-7.8%$1.470$1.478$1.2704,550,142
$1.410+0.040+2.9%$1.350$1.530$1.3505,116,347
$1.370-0.070-4.9%$1.485$1.485$1.3154,122,044
$1.440-0.110-7.1%$1.490$1.550$1.3305,391,417
$1.550+0.030+2.0%$1.530$1.700$1.5208,105,687
$1.520+0.220+16.9%$1.290$1.605$1.28015,086,505
$1.300+0.235+22.1%$1.060$1.390$1.04010,597,699
$1.065-0.045-4.1%$1.100$1.100$1.0332,244,136
$1.110-0.050-4.3%$1.110$1.130$1.0602,700,300
$1.160-0.080-6.5%$1.160$1.220$1.1155,122,600
$1.240+0.279+29.0%$0.998$1.310$0.99015,240,000
$0.961+0.044+4.8%$0.930$0.986$0.9004,092,800
$0.917-0.213-18.8%$1.130$1.140$0.9178,424,400
$1.130-0.170-13.1%$1.250$1.260$1.0906,935,800
$1.300-0.110-7.8%$1.371$1.390$1.09510,232,700
$1.410-0.190-11.9%$1.600$1.670$1.3809,457,700
$1.600+0.080+5.3%$1.430$1.790$1.39016,967,400
$1.520+0.140+10.1%$1.485$1.550$1.38015,076,400
$1.380+0.360+35.3%$1.040$1.400$1.00016,062,000
$1.020-0.045-4.2%$1.040$1.100$0.9604,875,800
$1.065+0.020+1.9%$1.050$1.100$1.0005,604,600
$1.045-0.155-12.9%$1.150$1.270$0.93617,042,600
$1.200+0.451+60.2%$0.781$1.350$0.76978,550,900
$0.749+0.043+6.1%$0.715$0.750$0.7093,656,800
$0.706-0.045-6.0%$0.750$0.760$0.7003,726,200
$0.751+0.008+1.1%$0.724$0.761$0.7104,585,600
$0.743-0.023-3.0%$0.751$0.770$0.7292,706,400
$0.766-0.031-3.9%$0.781$0.790$0.7284,042,400
$0.797-0.003-0.4%$0.804$0.822$0.7813,937,400
$0.800-0.024-2.9%$0.810$0.810$0.7506,097,400
$0.824-0.086-9.5%$0.880$0.906$0.8189,724,200
$0.910+0.068+8.1%$0.860$0.995$0.81224,750,000
$0.842+0.036+4.5%$0.937$0.970$0.80717,073,200
$0.806-0.036-4.3%$0.823$0.900$0.75118,976,900
$0.842-0.149-15.0%$0.908$0.998$0.82035,878,100
$0.991+0.406+69.4%$0.649$1.060$0.620196,516,300
$0.585+0.186+46.6%$0.492$0.755$0.413372,179,900
$0.399+0.104+35.3%$0.278$0.450$0.26180,847,300
$0.295-0.020-6.3%$0.320$0.320$0.2935,839,200
$0.315+0.022+7.5%$0.291$0.330$0.28512,732,500
$0.293-0.007-2.3%$0.300$0.318$0.28519,253,100
$0.300+0.080+36.4%$0.488$0.651$0.257491,124,600
$0.2200.0000.0%$0.220$0.238$0.2171,083,600
$0.220+0.008+3.8%$0.215$0.230$0.207832,600
$0.212+0.008+3.9%$0.201$0.218$0.201765,000
$0.204-0.010-4.7%$0.210$0.210$0.197591,500
$0.214+0.003+1.4%$0.210$0.232$0.2061,353,300
$0.211-0.007-3.2%$0.215$0.225$0.208837,700
$0.218-0.005-2.2%$0.224$0.234$0.2141,242,800
$0.223+0.002+0.7%$0.223$0.226$0.2151,197,600
$0.222+0.005+2.2%$0.219$0.229$0.2171,185,908
$0.217-0.002-1.0%$0.219$0.222$0.207697,412
$0.219+0.010+4.8%$0.208$0.236$0.2082,933,100
$0.209+0.008+4.0%$0.203$0.218$0.1982,008,700

Splits

1 split · NASDAQ:PDSB · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
Frankfurt:EU6
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All PDS Biotechnology Corporation news

PDS Biotechnology Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 236 in all · newest Nov 13, 2026 · oldest 2019
Calls
18 calls with a replay · 18 with a transcript · latest May 13, 2026
Decks
90 decks · latest Oct 21, 2026

Where PDS Biotechnology Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:PDSB · Home listingNASDAQUnited StatesUSD
LS Exchange:A2PF3FLS ExchangeGermanyEUR
gettex:EU6gettexGermanyEUR
Lang & Schwarz:A2PF3FLang & SchwarzGermanyEUR
Tradegate:EU6TradegateGermanyEUR
BOATS:PDSBBOATSUnited StatesUSD
Frankfurt:EU6 · This pageFrankfurtGermanyEUR
Dusseldorf:EU6DusseldorfGermanyEUR
Hamburg:EU6HamburgGermanyEUR
Munich:EU6MunichGermanyEUR
Stuttgart:EU6StuttgartGermanyEUR

Valuation

Price/book 7.1× against a median of 1.9×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$80.15M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
7.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.04

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
PDS Biotechnology Corporation · NASDAQ:PDSBUS$95.39MUS$80.15Mn/an/an/a7.1×n/a0.0×2.04
Unicycive Therapeutics, Inc. · NASDAQ:UNCYUS$97.77MUS$39.32Mn/an/an/a1.9×n/a0.0×1.09
NovaBridge Biosciences · NASDAQ:NBPUS$96.28MUS$68.30Mn/an/an/a3.2×n/a0.0×1.37
Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496US$96.17MUS$105.6Mn/a7.8×n/an/a−53.2%n/an/a
Immunic, Inc. · NASDAQ:IMUXUS$95.37M−US$36.09Mn/an/an/a0.9×n/a0.0×1.51
NRX Pharmaceuticals, Inc. · NASDAQ:NRXPUS$95.31MUS$76.46Mn/a17.7×n/an/a−458.5%n/a2.23
Allergy Therapeutics plc · LSE:AGYUS$95.27MUS$117.1Mn/a1.6×n/a17.1×−72.9%6.3×n/a
Voyager Therapeutics, Inc. · NASDAQ:VYGRUS$95.21M−US$11.60Mn/a−0.5×n/a0.7×−416.3%0.0×1.45
Outlook Therapeutics, Inc. · NASDAQ:OTLKUS$94.94MUS$83.70Mn/an/an/an/an/an/a1.10
Molecular Partners AG · SIX:MOLNUS$93.53M−US$4.92Mn/an/an/a1.0×n/a0.0×n/a
Sunhawk Vision Biotech, Inc. · TPEX:7759US$93.04MUS$82.43Mn/an/an/a7.3×n/a0.0×n/a
Median of the othersUS$95.29MUS$72.38M4.7×1.9×−244.6%0.0×1.41

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
4.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.44 · 1 analyst

Team and board

Officers

OfficerRole
Frank Bedu-AddoChief Executive Officer, Director
James BanaagSenior Vice President Finance, Corporate Strategy, Chief Financial Officer
Spencer BrownSenior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
Gregory ConnChief Scientific Officer
Kirk ShepardChief Medical Officer

Board

DirectorRole
Bruce WendelDirector
Deborah RamsdellDirector
Frank Bedu-AddoChief Executive Officer, Director
Ilian IlievDirector
James BanaagSenior Vice President Finance, Corporate Strategy, Chief Financial Officer
John DawsonDirector
Patrick Soon-ShiongDirector

Events

Calls

CallWhenStatus
PDS Biotechnology (NASDAQ:PDSB) Q1 2026 Earnings CallWed, May 13, 2026 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q4 2025 Earnings CallMon, Mar 30, 2026 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q3 2025 Earnings CallThu, Nov 13, 2025 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q2 2025 Earnings CallWed, Aug 13, 2025 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q1 2025 Earnings CallWed, May 14, 2025 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q4 2024 Earnings CallThu, Mar 27, 2025 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q3 2024 Earnings CallThu, Nov 14, 2024 · 8:30 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q4 2023 Earnings CallWed, Mar 27, 2024 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q2 2023 Earnings CallMon, Aug 14, 2023 · 8:00 AM ETReplay
All 18 calls
CallWhenStatus
PDS Biotechnology (NASDAQ:PDSB) Q1 2023 Earnings CallMon, May 15, 2023 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q4 2022 Earnings CallTue, Mar 28, 2023 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q3 2022 Earnings CallMon, Nov 14, 2022 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q2 2022 Earnings CallMon, Aug 08, 2022 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q1 2022 Earnings CallWed, May 11, 2022 · 11:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q4 2021 Earnings CallThu, Mar 31, 2022 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:00 AM ETReplay
PDS Biotechnology (NASDAQ:PDSB) Q2 2021 Earnings CallThu, Aug 12, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open−11.0%
Q2 2026Aug 13, 2026 · Before open−3.7%
Q1 2026May 13, 2026 · Before open+20.9%
Q4 2025Mar 26, 2026−14.7%
Q3 2025Nov 13, 2025 · After close−0.5%
Q2 2025Aug 13, 2025 · Before open−5.7%
Q1 2025May 14, 2025 · Before open+3.1%
Q4 2024Mar 25, 2025 · Before open−3.6%
Q3 2024Nov 14, 2024 · Before open−18.3%
Q2 2024Aug 13, 2024 · Before open0.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open−1.0%
Q4 2023Mar 27, 2024 · Before open−14.1%
Q3 2023Nov 14, 2023 · Before open+18.6%
Q2 2023Aug 14, 2023 · After close+10.3%
Q1 2023May 15, 2023 · Before open+7.4%
Q4 2022Mar 28, 2023 · Before open+3.0%
Q3 2022Nov 14, 2022 · Before open+26.1%
Q2 2022Aug 8, 2022 · Before open−2.3%
Q1 2022May 11, 2022 · Before open−15.9%
Q4 2021Mar 31, 2022 · Before open−1.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck28 slidesOct 21, 2026
Investor Presentation (September 2026)Investor deck28 slidesSeptember 2026
Q1 2026 Earnings PresentationEarnings21 slidesMay 13, 2026
Investor Presentation (April 2026)Investor deck21 slidesApr 24, 2026
Investor Presentation (February 2026)Investor deck22 slidesFeb 23, 2026
Investor Presentation (February 2026)Investor deck22 slidesFebruary 2026
Investor Presentation (August 2025)Investor deck22 slidesAug 25, 2025
Investor Presentation (August 2025)Investor deck22 slidesAugust 2025
Investor Presentation (June 2025)Investor deck23 slidesJun 25, 2025
Investor Presentation (June 2025)Investor deck23 slidesJune 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (February 2025)Investor deck24 slidesFeb 5, 2025
Corporate Update (November 2024)Corporate update27 slidesNov 14, 2024
Technical Presentation (October 2024)Technical12 slidesOct 2, 2024
Investor Presentation (September 2024)Investor deck27 slidesSeptember 2024
Investor Presentation (August 2024)Investor deck26 slidesAug 1, 2024
Investor Presentation (June 2024)Investor deck28 slidesJun 12, 2024
Investor Presentation (May 2024)Investor deck31 slidesMay 2024
Investor Presentation (March 2024)Investor deck17 slidesMarch 2024
Investor Presentation (December 2023)Investor deck54 slidesDec 4, 2023
Technical Presentation (October 2023)Technical57 slidesOct 3, 2023
Investor Presentation (October 2023)Investor deck45 slidesOct 3, 2023
ESWI 2023: Future Vaccination Strategies SessionConference10 slidesSep 19, 2023
Investor Presentation (September 2023)Investor deck41 slidesSep 11, 2023
Investor Presentation (August 2023)Investor deck40 slidesAug 18, 2023
Investor Presentation (June 2023)Investor deck38 slidesJun 14, 2023
Investor Presentation (May 2023)Investor deck40 slidesMay 17, 2023
Investor Presentation (May 2023)Investor deck38 slidesMay 2023
Investor Presentation (April 2023)Investor deck36 slidesApr 27, 2023
Technical Presentation (April 2023)Technical48 slidesApr 21, 2023
Investor Presentation (April 2023)Investor deck32 slidesApr 6, 2023
Investor Presentation (March 2023)Investor deck21 slidesMar 14, 2023
Investor Presentation (January 2023)Investor deck15 slidesJan 19, 2023
Investor Presentation (January 2023)Investor deck33 slidesJan 3, 2023
Investor Presentation (December 2022)Investor deck30 slidesDec 12, 2022
Technical Presentation (October 2022)Technical29 slidesOct 27, 2022
Investor Presentation (October 2022)Investor deck25 slidesOctober 2022
Investor Presentation (August 2022)Investor deck28 slidesAug 10, 2022
Investor Presentation (June 2022)Investor deck27 slidesJun 7, 2022
Corporate Update (June 2022)Corporate update15 slidesJun 7, 2022
Investor Presentation (May 2022)Investor deck24 slidesMay 11, 2022
Investor Presentation (March 2022)Investor deck25 slidesMar 15, 2022
Investor Presentation (March 2022)Investor deck24 slidesMar 15, 2022
Investor Presentation (January 2022)Investor deck23 slidesJan 27, 2022
Investor Presentation (January 2022)Investor deck22 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck38 slidesNovember 2021
Investor Presentation (October 2021)Investor deck38 slidesOct 18, 2021
Investor Presentation (October 2021)Investor deck27 slidesOct 5, 2021
Investor Presentation (September 2021)Investor deck36 slidesSep 9, 2021
Investor Presentation (September 2021)Investor deck27 slidesSeptember 2021
Investor Presentation (August 2021)Investor deck26 slidesAug 12, 2021

This page holds 50 of 90 decks. Open Decks

Open Decks

Financings

RaiseDate
Warrant exercise of common stock warrants (common stock or pre-funded warrants)
Closed: US$3.9M raised · US$0.22 a share
Buyers: NantWorks (exercised warrants to purchase an aggregate of 17,699,115 shares (or pre-funded warrants in lieu thereof))
Use of proceeds: Advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, PDS0101 partnership strategy and general corporate purposes
Nov 10, 2026
Private placement of units of common stock or pre-funded warrants with common warrants
Tranche closed: US$11.3M raised · US$0.2825 a unit · a Common Warrant to purchase one-half of one Private Placement Share
Buyers: Nant Capital, LLC (Led the round; obligated to purchase $10,000,000 at the Milestone Closing); AB Group Ltd. (Obligated to purchase $1,000,000 at the Milestone Closing)
Use of proceeds: Repay outstanding indebtedness, working capital and general corporate purposes, including clinical development, R&D and G&A expenses
Sep 14, 2026
Registered direct offering of shares of common stock (or pre-funded warrants) and accompanying warrants
Announced: about US$5.3M · US$0.91 a share · Warrants at US$1 for 60 months · Craig-Hallum
Dealers: Craig-Hallum (lead)
Use of proceeds: Continuation of the VERSATILE-003 Phase 3 trial, other research and development and general corporate purposes
Nov 11, 2025
Registered direct offering of shares of common stock (or common stock equivalents) and warrants
Announced: about US$11M · US$1.5 a share · Warrants at US$1.5 for 60 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Insiders: Certain directors of the Company participate at a combined purchase price of $1.66
Use of proceeds: Research and development expenses and general corporate purposes
Feb 27, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Edge Therapeutics, Inc. Priced at US$11.00 a share on Sep 30, 2015.

Price
US$11.00 a share
Shares offered
7,315,151 shares of common stock
Offering size
US$80.5 million
Underwriters' option
Up to 1,097,272 more shares
Underwriters
Leerink Partners, Credit Suisse, Guggenheim Securities, JMP Securities · In the order on the cover
Shares delivered
On or about Oct 6, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceMar 21, 2014
Filed publiclyAug 14, 2015
Amended onceSep 21, 2015
Shares registered with an exchangeSep 25, 2015
Declared effective by the SECSep 30, 2015
Final prospectus, with the priceOct 2, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Oct 2, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue60.5K59.8K57.3K49.1K246.4K176.3K98.4K69.1K182.9K100.1K
Gross profit-60.5K-59.8K-57.3K-49.1K-246.4K-176.3K-98.4K-69.1K-183.0K-100.0K
Research and development19.0M22.6M27.8M29.4M11.3M7.92M6.10M830.7K34.3M24.8M
Selling, general and administrative12.5M13.5M15.0M12.2M10.2M6.79M11.0M14.3M17.7M14.7M
Operating income-31.5M-36.3M-43.0M-41.7M-21.4M-14.9M-21.0M-3.65M-52.0M-39.5M
Depreciation and amortization21.8K21.1K17.4K865.36K15.6K98.4K69.1K182.9K100.1K
EBITDA-31.5M-36.3M-43.0M-41.7M-21.4M-14.9M-20.9M-3.58M-51.8M-39.4M
Interest expense5.34M4.67M4.21M1.32M0033.6K3.60K2.18M1.20M
Income before tax-35.7M-38.5M-44.3M-42.1M-21.4M-14.8M-7.38M-3.84M-53.4M-40.7M
Income tax-1.17M-869.2K-1.41M-1.20M-4.52M0-381.5K0-2.59M-1.85M
Net income-34.5M-37.6M-42.9M-40.9M-16.9M-14.8M-7.00M-3.84M-50.9M-38.8M
Earnings per share, basic-0.74-1.03-1.39-1.43-0.66-0.89-1.441.15-1.65-1.34
Earnings per share, diluted-0.74-1.03-1.39-1.43-0.66-0.89-1.441.15

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents26.7M41.7M56.6M73.8M65.2M28.8M12.2M103.7K88.1M106.4M
Receivables3.90K13.5K
Current assets28.3M45.1M59.1M76.5M66.8M30.3M14.5M122.1K89.1M107.4M
Property, plant and equipment120.2K142.0K134.1K0865.44K21.1K29.5K3.42M3.42M
Total assets30.5M45.4M59.4M77.0M67.2M30.9M14.5M164.4K92.6M110.9M
Accounts payable3.57M1.68M6.98M1.22M1.31M1.42M1.20M1.31M4.37M3.47M
Current liabilities9.48M17.1M13.6M9.82M3.76M3.27M2.79M1.91M12.9M6.68M
Long-term debt11.7M9.20M19.5M23.0M30.0K17.4M15.0M
Total debt16.9M21.8M23.9M23.5M490.4K610.3K30.0K20.5M15.0M
Total liabilities21.2M26.4M33.3M33.0M3.99M3.76M2.79M2.23M30.2M21.6M
Shareholders' equity9.25M19.0M26.1M44.0M63.2M27.1M11.7M-2.07M-609.5K89.3M
Shares outstanding54.9M38.0M33.1M30.2M28.4M22.3M5.28M3.42M30.9M28.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-27.8M-35.0M-33.6M-25.7M-12.5M-13.1M-18.1M-1.57M-40.7M-32.2M
Capital spending0-29.0K0-4-4-5-10-188.7K-686.7K
Free cash flow-27.8M-35.1M-33.6M-25.7M-12.5M-13.1M-18.1M-1.57M-40.9M-32.9M
Cash from investing0-29.0K0029.4M0-188.7K-686.7K
Cash from financing12.8M20.2M16.4M34.3M48.9M29.8M750.0K1.50M22.6M9.08M
Dividends paid-271
Share buybacks-27129.8M750.0K721.2K17.6M315.0K
Change in cash-15.0M-14.9M-17.3M8.58M36.4M16.7M12.1M-53.4M-18.3M-23.8M

Open Financials

Filings

FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementNov 20, 2026Meeting noticeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 10, 2026Current reportSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 20, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 20, 2026Insider tradeSEC
8-K · Current reportOct 20, 2026Current reportSEC
8-K · Current reportOct 20, 2026Management or board changeSEC
S-3 · Registration statementOct 14, 2026Offer documentSEC
8-K · Current reportOct 6, 2026Current reportSEC
8-K · Current reportSep 22, 2026Current reportSEC
SCHEDULE 13D · Big-stake noticeSep 21, 2026Big-stake noticeSEC
3 · Initial statement of ownershipSep 21, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 21, 2026Insider tradeSEC
8-K · Current reportSep 21, 2026Current reportSEC
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
8-K · Current reportSep 14, 2026Management or board changeSEC
8-K · Current reportSep 8, 2026Material contractSEC
8-K · Current reportSep 4, 2026Material contractSEC
8-K · Current reportAug 25, 2026Management or board changeSEC
8-K · Current reportAug 19, 2026Management or board changeSEC
8-K · Current reportAug 14, 2026Meeting outcomeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
8-K · Current reportAug 11, 2026Current reportSEC
8-K · Current reportJul 31, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJul 22, 2026Other filingsSEC
424B4 · ProspectusJul 21, 2026Offer documentSEC
S-3 · Registration statementJul 10, 2026Offer documentSEC
ARS · Annual report to shareholdersJun 26, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 26, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 26, 2026Meeting noticeSEC
424B5 · ProspectusJun 15, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementJun 15, 2026Meeting noticeSEC
8-K · Current reportJun 15, 2026Material contractSEC
8-K · Current reportJun 15, 2026Current reportSEC
8-K · Current reportJun 2, 2026Current reportSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
8-K · Current reportMay 1, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveApr 29, 2026Other filingsSEC
10-K/A · Annual report, amendedApr 28, 2026Annual reportSEC
S-3/A · Registration statement, amendedApr 27, 2026Offer documentSEC
CORRESP · Letter to the SECApr 24, 2026Other filingsSEC
8-K · Current reportApr 24, 2026Current reportSEC
8-K · Current reportApr 15, 2026Current reportSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
8-K · Current reportMar 3, 2026Current reportSEC
8-K · Current reportFeb 23, 2026Current reportSEC
8-K · Current reportFeb 20, 2026Current reportSEC
8-K · Current reportJan 28, 2026Current reportSEC
8-K · Current reportJan 22, 2026Current reportSEC
8-K · Current reportJan 9, 2026Current reportSEC
S-8 · Registration statement for employee plansDec 12, 2025Offer documentSEC
8-K · Current reportDec 9, 2025Current reportSEC
8-K · Current reportDec 2, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportNov 12, 2025ResultsSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
8-K · Current reportNov 10, 2025Current reportSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportSep 18, 2025Current reportSEC
UPLOAD · Letter from the SECSep 4, 2025Other filingsSEC
S-3 · Registration statementAug 29, 2025Offer documentSEC
8-K · Current reportAug 25, 2025Current reportSEC
8-K · Current reportAug 25, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
8-K · Current reportJul 10, 2025Current reportSEC
8-K · Current reportJun 25, 2025Current reportSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveJun 11, 2025Other filingsSEC
CORRESP · Letter to the SECJun 6, 2025Other filingsSEC
8-K · Current reportJun 2, 2025Current reportSEC
UPLOAD · Letter from the SECMay 30, 2025Other filingsSEC
S-3 · Registration statementMay 27, 2025Offer documentSEC
8-K · Current reportMay 22, 2025Current reportSEC
DEFR14AMay 22, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
8-K · Current reportMay 8, 2025Current reportSEC
DEFR14AMay 5, 2025Meeting noticeSEC
8-K · Current reportMay 2, 2025Material contractSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 24, 2025Management or board changeSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
8-K · Current reportMar 13, 2025Current reportSEC
8-K · Current reportMar 7, 2025Current reportSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
8-K · Current reportFeb 28, 2025Material contractSEC
424B5 · ProspectusFeb 28, 2025Offer documentSEC
8-K · Current reportFeb 26, 2025Current reportSEC
8-K · Current reportFeb 24, 2025Current reportSEC
8-K · Current reportFeb 5, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
8-K · Current reportOct 2, 2024Current reportSEC
8-K · Current reportSep 16, 2024Current reportSEC
8-K · Current reportSep 16, 2024Current reportSEC
424B5 · ProspectusAug 13, 2024Offer documentSEC
8-K · Current reportAug 13, 2024Material contractSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportAug 8, 2024Current reportSEC
8-K · Current reportAug 7, 2024Current reportSEC
8-K · Current reportAug 5, 2024Current reportSEC
8-K · Current reportAug 1, 2024Current reportSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
8-K · Current reportJun 24, 2024Meeting outcomeSEC
8-K · Current reportJun 12, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
8-K · Current reportMay 9, 2024Current reportSEC
8-K · Current reportMay 8, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedMay 8, 2024Big-stake noticeSEC
4 · Change in ownershipMay 2, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 2, 2024Insider tradeSEC
8-K · Current reportMay 2, 2024Management or board changeSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 18, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 27, 2024ResultsSEC
8-K · Current reportMar 13, 2024Current reportSEC
SC 13G · Big-stake noticeJan 29, 2024Big-stake noticeSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 23, 2024Insider tradeSEC
8-K · Current reportJan 22, 2024Management or board changeSEC
4 · Change in ownershipDec 4, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 4, 2023Insider tradeSEC
8-K · Current reportDec 4, 2023Current reportSEC
8-K · Current reportNov 28, 2023Management or board changeSEC
S-8 · Registration statement for employee plansNov 14, 2023Offer documentSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K · Current reportNov 9, 2023Current reportSEC
8-K · Current reportOct 23, 2023Current reportSEC
8-K · Current reportOct 11, 2023Current reportSEC
8-K · Current reportOct 3, 2023Current reportSEC
8-K · Current reportOct 3, 2023Current reportSEC
8-K · Current reportOct 3, 2023Current reportSEC
8-K · Current reportOct 2, 2023Current reportSEC
8-K · Current reportSep 20, 2023Current reportSEC
8-K · Current reportSep 11, 2023Current reportSEC
8-K · Current reportSep 8, 2023Current reportSEC
8-K · Current reportAug 18, 2023Current reportSEC
8-K · Current reportAug 17, 2023Current reportSEC
8-K · Current reportAug 14, 2023Current reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJul 25, 2023Current reportSEC
4 · Change in ownershipJul 17, 2023Insider tradeSEC

This page holds 200 of 806 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from PDS Biotechnology Corporation’s releases · as of Nov 10, 2026

Common shares
122,704,544
Fully diluted
130,955,979

Fully diluted

LineSharesAs of
Common shares122,704,544
Warrants8,251,435Sep 11, 2026

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Nov 22, 2026122,704,544

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard2.04M1.9%US$1.53MSep 30, 2026
Militia Capital Management LLC1.66M1.6%US$1.25MSep 30, 2026
Susquehanna790K0.75%US$593KSep 30, 2026
Renaissance Technologies621K0.59%US$466KSep 30, 2026
Geode Capital616K0.59%US$463KSep 30, 2026
BlackRock599K0.57%US$450KSep 30, 2026
Quantinno Capital Management LP552K0.53%US$414KSep 30, 2026
Focus Partners Wealth552K0.53%US$414KSep 30, 2026
Jane Street511K0.49%US$383KSep 30, 2026
Blair William & Co300K0.29%US$225KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Virtu Financial LLC279K0.27%US$210KSep 30, 2026
Acadian Asset Management LLC239K0.23%US$179KSep 30, 2026
UBS235K0.22%US$177KSep 30, 2026
Inspirion Wealth Advisors, LLC188K0.18%US$141KSep 30, 2026
Tocqueville Asset Management L.P.174K0.17%US$130KSep 30, 2026
Simplex Trading, LLC138K0.13%US$103KSep 30, 2026
State Street133K0.13%US$100KSep 30, 2026
Northern Trust127K0.12%US$94,965Sep 30, 2026
Commonwealth Equity Services, LLC118K0.11%US$88,580Sep 30, 2026
XTX Topco Ltd116K0.11%US$87,213Sep 30, 2026
Group One Trading LLC109K0.10%US$81,937Sep 30, 2026
Wells Fargo109K0.10%US$81,826Sep 30, 2026
Provenance Wealth Advisors, LLC78,8460.08%US$59,190Sep 30, 2026
BNY68,4910.07%US$51,416Sep 30, 2026
Tempus Wealth Planning, LLC61,8000.06%US$46,393Sep 30, 2026
Stifel Financial Corp60,0000.06%US$45,042Sep 30, 2026
Iron Gate Global Advisors LLC58,3730.06%US$43,821Sep 30, 2026
Clearstead Advisors, LLC50,0000.05%US$37,535Sep 30, 2026
JPMorgan49,9650.05%US$37,119Sep 30, 2026
Osaic Holdings, Inc.45,2000.04%US$33,769Sep 30, 2026
Everhart Financial Group, Inc.38,0000.04%US$28,527Sep 30, 2026
StoneX Group Inc.37,5920.04%US$19,179Sep 30, 2026
Rockefeller Capital Management L.P.29,6640.03%US$22,269Sep 30, 2026
Morgan Stanley24,7220.02%US$18,559Sep 30, 2026
Federation des caisses Desjardins du Quebec21,8000.02%US$16,372Sep 30, 2026
Creative Planning17,4530.02%US$13,102Sep 30, 2026
Signature Wealth Management Partners, LLC13,8480.01%US$10,396Sep 30, 2026
Wealth Group, Ltd.13,3990.01%US$10,000Sep 30, 2026
Two Sigma13,1700.01%US$9,887Sep 30, 2026
Ground Swell Capital, LLC12,0540.01%US$9,049Sep 30, 2026
PNC Financial Services Group, Inc.11,9000.01%US$8,937Sep 30, 2026
Northwestern Mutual Wealth Management Co10,9720.01%US$8,237Sep 30, 2026
DAVENPORT & Co LLC10,000<0.01%US$7,507Sep 30, 2026
Grandfield & Dodd, LLC10,000<0.01%US$7,507Sep 30, 2026
Creative Financial Designs Inc3,000<0.01%US$2,252Sep 30, 2026
Jones Financial Companies Lllp2,000<0.01%US$1,594Sep 30, 2026
Blume Capital Management, Inc.2,000<0.01%US$1,502Sep 30, 2026
Tower Research Capital LLC (TRC)1,579<0.01%US$1,185Sep 30, 2026
BNP Paribas648<0.01%US$486Sep 30, 2026
Rialto Wealth Management, LLC507<0.01%US$381Sep 30, 2026

This page holds 50 of 58 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.04M0.99%US$918KJun 30, 2026
Vanguard Extended Market Index Fund584K0.56%US$515KJun 30, 2026
Fidelity Extended Market Index Fund292K0.28%US$315KMay 31, 2026
iShares Micro-Cap ETF190K0.18%US$167KJun 30, 2026
Fidelity Total Market Index Fund97,9310.09%US$106KMay 31, 2026
Fidelity Series Total Market Index Fund88,4190.08%US$95,493May 31, 2026
Vanguard Institutional Total Stock Market Index Fund47,6190.05%US$41,957Jun 30, 2026
Vanguard Balanced Index Fund25,6950.02%US$22,640Jun 30, 2026
Fidelity Nasdaq Composite Index Fund15,3120.01%US$16,537May 31, 2026
1290 VT Micro Cap Portfolio12,7940.01%US$11,273Jun 30, 2026
All 11 holders
HolderSharesOf the companyValueAs of
Knights of Columbus U.S. ALL CAP INDEX FUND311<0.01%US$213Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Nant Capital, LLC19.90%22.9MNov 9, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Liam Ratcliffe
Other companies: OnKure Therapeutics, Inc. (Director · Since at least Mar 27, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Climb Bio, Inc. (Director · Aug 9, 2021 – Jun 26, 2024 · Past); Passage Bio, Inc. (Director · Feb 27, 2020 – May 27, 2021 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 29, 2019 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – May 17, 2018 · Past)
Director · Jun 21, 2016 – Mar 15, 2019 · Past
Sol J. Barer
Other companies: Teva Pharmaceutical Industries Limited (Director · Since at least Jan 1, 2018); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); CervoMed Inc. (Director · Nov 1, 2013 – Jul 24, 2014 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past)
Director · Sep 30, 2015 – Mar 15, 2019 · Past
Isaac Blech
Other companies: X4 Pharmaceuticals, Inc. (Director · Mar 13, 2019 – Mar 13, 2019 · Past); Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Aug 13, 2018 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); CervoMed Inc. (Director · Jul 24, 2014 – Aug 31, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past)
Director · Sep 30, 2015 – Mar 15, 2019 · Past
Robert J. Spiegel
Other companies: Ernexa Therapeutics Inc. (Director · Since at least Sep 14, 2026); RenovoRx, Inc. (Director · Since at least Apr 25, 2023); Geron Corporation (Director · Since at least Sep 29, 2017); Athenex Inc (Director · Aug 4, 2020 – Apr 21, 2023 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Bio Green Med Solution, Inc. (Director · Sep 6, 2018 – Jun 30, 2023 · Past); Sucampo Pharmaceuticals Inc (Director · Feb 13, 2018 – Feb 13, 2018 · Past)
Director · Jun 19, 2018 – Mar 15, 2019 · Past
Andrew Saik
Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); Arvinas, Inc. (Chief Financial Officer and Treasurer · Since at least Jun 24, 2024); Intercept Pharmaceuticals Inc (EVP & Chief Financial Officer · Jun 21, 2021 – Nov 8, 2023 · Past); VYNE Therapeutics Inc. (Chief Financial Officer · Sep 8, 2020 – May 28, 2021 · Past); Auxilium Pharmaceuticals Inc (CFO · Aug 18, 2014 – Jan 29, 2015 · Past)
Chief Financial Officer, Director · Oct 31, 2017 – Feb 14, 2020 · Past
Patrick Soon-Shiong
Other companies: ImmunityBio, Inc. (Executive Chairman of the Board · Since at least Jul 27, 2015); tronc Inc (Director · Nov 4, 2016 – Mar 20, 2017 · Past); Nanthealth LLC (Chief Executive Officer, Director · Jun 1, 2016 – Aug 28, 2023 · Past); Abraxis BioScience Inc (Executive Chairman, Director · Nov 7, 2007 – Oct 15, 2010 · Past); APP Pharmaceuticals Inc (Director · Dec 31, 2005 – Sep 10, 2008 · Past)
Director · Since at least Sep 14, 2026
Rosemary A. Crane
Other companies: Certara, Inc. (Director · Since at least Jul 21, 2022); Teva Pharmaceutical Industries Limited (Independent Director · Since at least Jan 1, 2018); Tarsus Pharmaceuticals, Inc. (Director · Aug 11, 2021 – Jun 24, 2024 · Past); Catalent Inc (Director · Feb 16, 2018 – Oct 27, 2023 · Past); Unilife Corp (Director · Oct 28, 2016 – Oct 28, 2016 · Past)
Director · Sep 18, 2017 – Mar 15, 2019 · Past
Bruce Wendel
Other companies: ImmunityBio, Inc. (Director · Since at least Dec 12, 2025); GT Biopharma, Inc. (Director · Nov 11, 2020 – Jan 27, 2023 · Past); Verastem, Inc. (Director · Jun 14, 2016 – Jun 16, 2020 · Past); Abraxis BioScience Inc (Chief Executive Officer, Director · Nov 7, 2007 – Oct 15, 2010 · Past)
Director · Since at least Oct 20, 2026
Otis W. Brawley
Other companies: Agilent Technologies, Inc. (Director · Since at least Nov 17, 2021); Incyte Corporation (Director · Since at least Sep 27, 2021); Lyell Immunopharma, Inc. (Director · Since at least Jun 16, 2021); Theragenics Corp (Director · May 9, 2006 – May 18, 2007 · Past)
Director · Since at least Nov 3, 2020
Stephen C. Glover
Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 1, 2026); ZyVersa Therapeutics, Inc. (Co-founder, Chairman, CEO, and President · Since at least Dec 12, 2022); Ambrx Biopharma Inc. (Director · May 18, 2023 – Mar 7, 2024 · Past); Insmed Incorporated (President Follow-on Biologics · Jun 22, 2007 – Mar 31, 2009 · Past)
Director · Since at least Apr 2, 2019
All 38 people
PersonSeat
Albert N Marchio II
Other companies: NexImmune, Inc. (See Remarks · Apr 5, 2024 – Apr 5, 2024 · Past); Fresh Tracks Therapeutics Inc. (CEO and CFO, Director · Jan 24, 2023 – Dec 28, 2023 · Past); Brickell Biotech Inc (Chief Financial Officer · Dec 1, 2020 – May 5, 2022 · Past)
Chief Accounting & Adm Officer · Sep 30, 2015 – Dec 31, 2018 · Past
Andrew Einhorn
Other companies: Pelthos Therapeutics Inc. (Director · Since at least Dec 23, 2025); Cognition Therapeutics, Inc. (Interim CFO · Aug 12, 2022 – Aug 12, 2022 · Past); Medavail Holdings Inc (Chief Financial Officer · Oct 15, 2012 – Oct 15, 2012 · Past)
Chief Financial Officer · Sep 30, 2015 – Mar 1, 2017 · Past
Gregory G. Freitag
Other companies: ZyVersa Therapeutics, Inc. (Principal of FreiMc · Since at least Jan 5, 2023); Pressure BioSciences, Inc. (Director · Jul 27, 2010 – Apr 5, 2012 · Past); Axogen, Inc. (Director · Jun 1, 2010 – Jun 4, 2024 · Past)
Director · Since at least Mar 15, 2019
James J Loughlin
Other companies: InspireMD Inc. (Director · Sep 21, 2012 – Mar 21, 2016 · Past); Celgene Corporation (Director · Jan 8, 2007 – Nov 20, 2019 · Past); Datascope Corp (Director · Jan 1, 2006 – Jan 30, 2009 · Past)
Director · Sep 30, 2015 – Jun 28, 2019 · Past
Mathew C Hill
Other companies: Apyx Medical Corporation (Chief Financial Officer · Since at least Dec 4, 2023); STRATA Skin Sciences, Inc. (Chief Financial Officer · May 15, 2018 – Nov 13, 2020 · Past); Ep Medsystems Inc (Chief Financial Officer · Dec 12, 2006 – Dec 12, 2006 · Past)
Chief Financial Officer · Oct 18, 2021 – Jan 5, 2023 · Past
W Bradford Middlekauff
Other companies: Amanat Acquisition Corp (Director · Since at least May 18, 2026); Tourmaline Bio Inc. (CBO, GC and Secretary · Since at least Oct 19, 2023); Immunovant, Inc. (General Counsel · Dec 18, 2019 – May 15, 2020 · Past)
Senior VP, GC and Secretary · Oct 30, 2015 – Mar 18, 2019 · Past
Kamil Ali-Jackson
Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Dec 16, 2021); Aclaris Therapeutics, Inc. (Chief Legal Officer · Dec 15, 2020 – Jan 3, 2022 · Past)
Director · Since at least Jun 15, 2021
Seth Van Voorhees
Other companies: NRX Pharmaceuticals, Inc. (CHIEF FINANCIAL OFFICER · Jun 13, 2022 – Dec 16, 2022 · Past); Research Frontiers Incorporated (CFO & VP-Business Development · Dec 31, 2017 – Feb 21, 2020 · Past)
Chief Financial Officer · Jan 1, 2021 – Jun 15, 2021 · Past
DeLyle W Bloomquist
Other companies: Rayonier Advanced Materials Inc. (President and CEO, Director · Since at least Jun 27, 2014)
Director · Mar 15, 2019 – Jun 23, 2020 · Past
Stephan Toutain
Other companies: Interleukin Genetics Inc (Chief Commercial Officer · Aug 15, 2016 – Apr 19, 2017 · Past)
Chief Operating Officer · Since at least May 1, 2024
Alpaslan YamanV.P., Technical Ops. & Mfg. · Sep 30, 2015 – Mar 13, 2017 · Past
Arnold James BanaagDirector · Since at least Sep 14, 2026
Deborah RamsdellDirector · Since at least Oct 20, 2026
Frank Bedu-AddoPresident/CEO, Director · Since at least Mar 15, 2019
Frank Bedu-AddoChief Executive Officer, Director · Since at least Oct 20, 2026
Gregory ConnChief Scientific Officer · Since at least Mar 15, 2019
Herbert J FaleckChief Medical Officer · Sep 30, 2015 – Dec 31, 2018 · Past
Ilian IlievDirector · Since at least Apr 8, 2020
James BanaagSenior Vice President Finance, Corporate Strategy, Chief Financial Officer · Since at least Oct 20, 2026
Janetta TrochimiukPrincipal Accounting Officer · Since at least Mar 23, 2020
John DawsonDirector · Since at least Oct 20, 2026
Kirk ShepardChief Medical Officer · Since at least Jan 22, 2024
Kurt G ContiDirector · Sep 30, 2015 – Mar 23, 2018 · Past
Lars BoesgaardChief Financial Officer · Since at least Dec 4, 2023
Lauren WoodChief Medical Officer · Jan 5, 2023 – Jan 5, 2023 · Past
Renu VaishV.P., Global Reg. Affairs · Sep 30, 2015 – Jun 16, 2016 · Past
Richard SykesDirector · Mar 15, 2019 – Jun 24, 2024 · Past
Spencer BrownSenior Vice-President, General Counsel, Corporate Secretary and Compliance Officer · Since at least Jun 1, 2022

Open People

Log in to ask 6ix AI your own questions about PDS Biotechnology Corporation.